Voglibose

Voglibose

Voglibose (CAS No. 83480-29-9) is an alpha-glucosidase inhibitor used primarily in the management of postprandial blood glucose levels in patients with type 2 diabetes mellitus. It works by delaying the digestion and absorption of carbohydrates in the small intestine, thereby reducing spikes in blood sugar after meals.

Chemical Properties

• Molecular Formula: C₁₀H₂₁NO₇
• Molecular Weight: 267.28 g/mol
• Boiling Point: 601.9 °C at 760 mmHg
• Melting Point: 162–163 °C
• Density: 1.58 ± 0.1 g/cm³
• Appearance: Off-white powder
• Optical Rotation: +26.2° (c=1, in H₂O)
• Storage Conditions: Store at 2–8 °C for long-term stability (months).

Mechanism of Action

Voglibose inhibits the activity of alpha-glucosidase enzymes located in the brush border of the small intestine, which are responsible for breaking down complex carbohydrates into simple sugars. By inhibiting these enzymes, Voglibose effectively slows down carbohydrate absorption, leading to a reduction in postprandial hyperglycemia (PPHG).

Clinical Applications

1. Diabetes Management:
   • Primarily used to control postprandial blood glucose levels in individuals with type 2 diabetes.
   • Helps prevent sudden increases in blood sugar after meals, making it an essential part of diabetes management strategies.
2. Combination Therapy:
   • Can be used alongside other antidiabetic medications, such as metformin or sulfonylureas, to enhance glycemic control.

Dosage and Administration

Voglibose is typically taken orally immediately before each meal, with a recommended maximum dosage of 0.6 mg taken three times daily. The exact dosage may vary based on individual patient factors.

Side Effects

Common side effects associated with Voglibose include gastrointestinal discomfort, such as flatulence, diarrhea, and abdominal pain. These effects are generally mild and manageable but should be monitored.

Safety Profile

Voglibose is considered safe for use in patients with mild to moderate renal impairment; however, it should be avoided in individuals with severe renal conditions.

Conclusion

Voglibose is a valuable therapeutic agent for managing blood glucose levels in type 2 diabetes patients by inhibiting carbohydrate absorption and reducing postprandial spikes in blood sugar. Its effectiveness, combined with a generally favorable safety profile, makes it an important option in diabetes care.

Citations:

1. https://www.carehospitals.com/medicine-detail/voglibose
2. https://en.wikipedia.org/wiki/Voglibose
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3919386/
4. https://go.drugbank.com/drugs/DB04878
5. https://www.selleckchem.com/products/voglibose.html
6. https://www.kavyapharma.com/products/pharmaceutical-products/api-bulk-drugs/voglibose/
7. https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sa=X&ved=2ahUKEwiu6qaw5KSMAxVAlu4BHUAeDz0Q_B16BAgFEAI